ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple
oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited